Zhongguo (Roy) Zhou

Contact: zhzhou@scripps.edu

Major Research Interests

Multidisciplinary management of hepatocellular carcinoma, including surgery, local ablation, embolization, target & systemic therapy, both in clinical and basic research.

Education: 

1. 2001.9-9-2006.6 Sun Yat-Sen University of Medical Sciences, P.R. China, Bachelor of Medicine.

2. 2006.09-2011.6 Sun Yat-Sen University Cancer Center, P.R. China, Ph.D of Oncology

4. 2009.12-12-2010.12 Visiting Ph.D student, Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, USA
5. 2013.3-2013.3 Visiting Scholar, Department of Pathology and Molecular Biology,University of California, San Diego, USA

Employment:  

1. 2011.08 - 2012.12 Resident, Department of Hepatobiliary & Pancreatic Surgery, Sun Yat-Sen University Cancer Center, GuangZhou, China
2. 2013.01 - 2016.12 Attending, Department of Hepatobiliary & Pancreatic Surgery, Sun Yat-Sen University of Medical Sciences, GuangZhou, China
3. 2017.01 – 2018.12 Associate Professor, Department of Hepatobiliary & Pancreatic Surgery, Sun Yat-Sen University Cancer Center, GuangZhou, China.
4. 2018.12 – present Postdoc, The Scripps Research Institute, Department of Cell and Molecular Biology

Honors

1. 35 Most Potential Young Oncologists under the age of 35, Chinese Society of Clinical Oncology, 2017.
2. Speaker, 20th annual meeting of Chinese Society of Clinical Oncology, 2017.
3. Sun Yat-sen University Cancer Young Clinical Medical Scientist, 2017.
4. Speaker, MD Anderson Cancer Center Global Academic Program, Houston, USA. 2017.
5. Outstanding paper of 5th Guangzhou International Symposium of Oncology,2016
6. National Champion, Standardized treatment of hepatocellular carcinoma cases PK competition, 2015.
7. Guangdong Champion, 3rd National Academy of general surgeons' academic papers competition,2015.
8. Excellent teacher of clinical medicine,Sun Yat-sen University,2015.
9. Travel Award& Outstanding poster of MD Anderson Cancer Center Global Academic Program, Korea, 2014.
10. Speaker, 4th International Symposium Thymosins in Health and Disease,Italy, 2014.
11. Champion of Young teachers' English teaching competition, Sun Yat-sen University

Grants (Principle investigator)

1. Mechanism of TACC3 mediating recurrence and metastasis of hepatocellular carcinoma after radiofrequency ablation, National Natural Science Foundation of China, 2016.
2. Young Clinical Medical Scientist Project of Sun Yat-sen University Cancer Center, 2017.
3. TACC3 regulation of stem cell like characteristics, invasion and metastasis of hepatocellular carcinoma, Guangdong Key Laboratory of Liver Disease Research, 2017.
4. Antitumor effect of Pim kinase inhibitor on colon cancer , Guangdong Academy of medical science and Technology Research Fund, 2012.

Publications (Corresponding/First Author, Last 3 years)

1. Huang Z, Zheng W, Zhang YJ, Xu L, Chen JB, Chen JC, Chen MS, Zhou Z. Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study. Ultrasound in medicine & biology 2017;43(11): 2522-2529.
2. Chen JC, Zhang RX, Chen MS, Xu L, Chen JB, Yang KL, Zhang YJ, Zhou ZG. Left jackknife position: a novel position for laparoscopic hepatectomy. Chinese journal of cancer 2017;36(1): 31.
3. Zhou ZG, Chen JB, Qiu HB, Wang RJ, Chen JC, Xu L, Chen MS, Zhang YJ. Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget 2016;7(19): 27938-27945.
4. Zhou D-S, Wang H-B, Zhou Z-G, Zhang Y-J, Zhong Q, Xu L, Huang Y-H, Yeung S-C, Chen M-S, Zeng M-S. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 2015;6(27): 24163-24177.
5. Qiu SJ, Zhou ZG, Shen F, Li AJ, Chen MS, Ying MG, Chen Z, Zhang YX, Sun HC, Fan J. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol. Expert opinion on biological therapy 2015;15 Suppl 1: S133-137.
6. Zhou Z, Zhang R, Wang R, Zhang Y, Xu L, Chen J, Zhang J, Huang Z, Chen M, Pan Z. Expression of Pim-3 in colorectal cancer and its relationship with prognosis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016;37(7): 9151-9156.
7. Zhou Z, Chen Z, Chen M, Wang R, Yin Y, Yao Y. Clinicopathologic factors predicting outcomes in patients with gastrointestinal stromal tumors of the rectum and colon. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35(5): 4357-4362.
8. Zhang J, Zhou ZG, Huang ZX, Yang KL, Chen JC, Chen JB, Xu L, Chen MS, Zhang YJ. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chinese journal of cancer 2016;35: 25.
9. Zhou ZG, Zheng XR, Zhou Q, Shi M, Zhang YJ, Guo RP, Yuan YF, Chen MS, Lin XJ, Lao XM, Li SP. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese journal of cancer 2015;34(5): 205-216.
10. Zhang RX, Zhou ZG, Lu SX, Lu ZH, Wan DS, Pan ZZ, Wu XJ, Chen G. Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients. Scientific reports 2017;7(1): 16043.

___________

Lab Home
___________

About SLTSR
___________

Principal Investigators
___________

Lab Members
___________

Alumni
___________

Collaborators
___________

Publications
___________

News
___________

Photos
___________

Protocols
___________

Members Only
___________

Joining SLTSR
___________

Contact Us
___________